Posts in Regulatory Affairs

Paediatric Investigation Plans: Planning for the Youngest Patients

For most new medicines, developing for adults is only part of the obligation. The Paediatric Investigation Plan determines what a company must do for children[…]

The Clinical Trials Regulation: Life After the Transition

Since the start of 2025, there is only one way to run a clinical trial in the EU. The Clinical Trials Regulation and its portal,[…]

The Clinical Trials Regulation and CTIS: One Portal, One Assessment

The Clinical Trials Regulation (EU) No 536/2014 has reshaped how trials are authorised across Europe. Since the three-year transition period closed on 31 January 2025,[…]

ISO 27001 and Data Integrity: Information Security Risks in a GxP Environment

Information security has quietly become a GMP concern. As pharmaceutical operations move to cloud platforms, connected instruments and AI-assisted systems, the confidentiality and integrity of[…]

The EU Medical Technology Framework: A Compliance Roadmap for 2026 and Beyond

The European Union’s medical technology rulebook — the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) — is the most demanding device[…]

The In Vitro Diagnostic Regulation: Transition Deadlines and the Path to Compliance

The In Vitro Diagnostic Medical Devices Regulation (IVDR), Regulation (EU) 2017/746, has applied since 26 May 2022, replacing the long-standing In Vitro Diagnostic Directive (98/79/EC).[…]

Paediatric Investigation Plans: Planning for Children from the Start

For most new medicines in the EU, studying the product in children is not optional. Under the Paediatric Regulation, a paediatric investigation plan (PIP) must[…]

Advanced Therapy Medicinal Products: Navigating the EU Regulatory Pathway

Advanced therapy medicinal products (ATMPs) — gene therapies, somatic-cell therapies and tissue-engineered products — are among the most complex products to bring to the European[…]

Orphan Drug Designation in the EU: Framework and Reform

Orphan designation is one of the most valuable regulatory assets in Europe — and the rules that govern it are about to change for the[…]

Variations and Lifecycle Management: What Changed for 2026

The EU variations framework has just been through its most significant revision in over a decade — and the rules changed on a different date[…]